Results 161 to 170 of about 3,103 (172)

Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis

Journal of Cystic Fibrosis, 2022
Max C Petersen
exaly  

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older – The RECOVER Trial

American Journal of Respiratory and Critical Care Medicine, 2023
Paul Mcnally, Michael Williamson, Edward Mckone   +2 more
exaly  

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial

American Journal of Respiratory and Critical Care Medicine, 2023
Paul Mcnally, Jane C Davies
exaly  

Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis

Frontiers in Pharmacology, 2023
Zijing Zhou, Zhihong Zuo, Zuo Zhihong
exaly  

Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor

Organic Process Research and Development, 2019
David L Hughes
exaly  

Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events

American Journal of Respiratory and Critical Care Medicine
Bonnie Ramsey, David R Demaso, Edward Mckone   +2 more
exaly  

Elexacaftor/tezacaftor/ivacaftor

Reactions Weekly
openaire   +1 more source

Elexacaftor/ivacaftor/tezacaftor

Reactions Weekly, 2020
openaire   +1 more source

Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor

Frontiers in Pharmacology
E Polverino
exaly  

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study

American Journal of Respiratory and Critical Care Medicine
Hiran Selvadurai, Bonnie Ramsey
exaly